These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 23819994)

  • 1. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years.
    Liu B; Wen X; Huang C; Wei Y
    Int J Biochem Cell Biol; 2013 Sep; 45(9):1987-96. PubMed ID: 23819994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling.
    Chen J; Xu W; Chen Y; Xie X; Zhang Y; Ma C; Yang Q; Han Y; Zhu C; Xiong Y; Wu K; Liu F; Liu Y; Wu J
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of p38 MAPK/STAT3 To Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism.
    Yang Q; Zhang Q; Zhang X; You L; Wang W; Liu W; Han Y; Ma C; Xu W; Chen J; Yang H; Wan P; Zhou Y; Liu Y; Wu K; Yang Z; Wu J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
    Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
    Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.
    Kim SY; Kim H; Kim SW; Lee NR; Yi CM; Heo J; Kim BJ; Kim NJ; Inn KS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
    Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
    J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
    Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
    Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.
    Guner R; Karahocagil M; Buyukberber M; Kandemir O; Ural O; Usluer G; Inan D; Koksal I; Baykam N; Hizel K; Yamazhan T; Esen S; Tasyaran MA
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1185-91. PubMed ID: 21934508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication.
    Takehara T; Suzuki T; Ohkawa K; Hosui A; Jinushi M; Miyagi T; Tatsumi T; Kanazawa Y; Hayashi N
    J Hepatol; 2006 Feb; 44(2):267-74. PubMed ID: 16226822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
    Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
    Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
    Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
    Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks.
    Korba BE; Cote P; Hornbuckle W; Schinazi R; Gangemi JD; Tennant BC; Gerin JL
    Antivir Ther; 2000 Jun; 5(2):95-104. PubMed ID: 10971862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.